Previous Article | Next Article 
Journal of Virology, April 2007, p. 4357-4362, Vol. 81, No. 8
0022-538X/07/$08.00+0 doi:10.1128/JVI.02639-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
New Natural Intergenotypic (2/5) Recombinant of Hepatitis C Virus
Florence Legrand-Abravanel,
Julie Claudinon,
Florence Nicot,
Martine Dubois,
Sabine Chapuy-Regaud,
Karine Sandres-Saune,
Christophe Pasquier, and
Jacques Izopet*
Laboratoire de Virologie, Institut Fédératif de Biologie, INSERM U563-IFR30, 330 Avenue de Grande-Bretagne, TSA 40031, 31059 Toulouse Cédex 9, France
Received 29 November 2006/
Accepted 19 January 2007

ABSTRACT
A 9.2-kb sequence from a hepatitis C virus (HCV) strain found
in southwest France was compared to sequences from reference
strains in HCV sequence databases. We found a recombinant virus
with genotype 2 at the 5' end and genotype 5 at the 3' end.
The crossover point was located between genes NS2 and NS3. Recombination
between HCV genotypes must now be considered in studies on HCV
epidemiology and evolution and in predictions of the virus response
to antiviral therapy. Knowing the location of the recombination
point may also be useful for constructing infectious chimeric
viruses.

TEXT
Studies of the nucleotide sequences of hepatitis C virus (HCV)
variants from different individuals and geographical regions
have revealed at least six genotypes and many subtypes (
15,
16). The genotype is presently a major factor in the choice
of treatment and the prognosis (
2,
7). Knowledge of the distributions
of genotypes in different parts of the world may help us to
understand the epidemiology and evolution of HCV. Until 2001,
the evolution of HCV was thought to proceed in a clonal manner,
with diversity generated through the accumulation of mutations.
However, homologous recombinations have been demonstrated in
places as far apart as St. Petersburg (
5), Vietnam (
10), the
Philippines (
4), and Peru (
1). We have now identified a new
natural intergenotypic recombinant. Full-genome sequencing indicated
that it was produced by recombination between genotypes 2 and
5.
Identification of a potential recombinant strain of HCV.
We previously analyzed the responses to treatment of 26 patients infected with HCV genotype 5 (HCV-5) in southwest France and the associated epidemiology (6). Phylogenetic analysis of the NS5B genes of the 26 corresponding strains pointed out a particular strain, R1. Twenty-five local strains formed a cluster with the genotype 5a reference sequences, while the R1 strain formed a distinct branch in the tree (Fig. 1A). The NS5B sequence with accession number AY373486 corresponds to the strain called R1 in the present study. The E2 region of the genome was sequenced to further characterize this strain (12). The MEGA program showed that the R1 sequence belonged to the genotype 2 in the E2 phylogenetic tree (Fig. 1B), but the strain could not be subtyped. Although these preliminary analyses were compatible with a recombinant strain of HCV, they could also indicate a mixed infection with two genotypes. Two genome regions were cloned and sequenced using the Invitrogen TA cloning kit. Phylogenetic analysis indicated that all the clones from the 5' untranslated region (UTR; n = 19) clustered with genotype 2 and all the clones from the NS5B region (n = 35) clustered with genotype 5 (data not shown). This result excluded a double infection.
Determination of the entire sequence of the R1 strain.
cDNA was synthesized with reverse transcriptase (Superscript
II; Invitrogen) and an RNase inhibitor (RNaseOUT; Invitrogen).
A 7,400-nucleotide (nt) fragment was amplified and cloned using
the Expand long-template PCR system (Roche Diagnostics, France)
with sense primer KS3-2a and antisense primer ENO2 (Table
1).
The other parts of the genome were directly sequenced. Almost
the whole genome was sequenced (9,246 nt) with the Applied Biosystems
Taq polymerase kit. The structure of the HCV genome was checked
using the sequence locator tool (
http://hcv.lanl.gov/content/hcv-db/LOCATE/locate.html).
The various regions of the HCV genome were identified, and no
stop codon was identified. The R1 sequences downstream (fragment
of 3,430 nt) and upstream (fragment of 5,390 nt) of the putative
breakpoint were compared with reference sequences (Fig.
2).
The 5' end of R1, from the 5' UTR to NS2, corresponded to genotype
2, while the 3' part of the R1 sequence, from NS3 to NS5B, was
closer to that of genotype 5.
Identification of the recombination point.
Recombination analysis was performed with the Recombinant Detection
Program version 2 (
http://darwin.uvigo.es/rdp/rdp.html) (
8).
This tool provides statistical evidence for the breakpoint site
by using six methods (Recombinant Detection Program, Geneconv,
BOOTSCAN, maximum chi-square, Chimaera, and sister scanning
analyses). Recombination analyses of the R1 sequence and genome
2k (AB0331663), genome 2c (D50409), genome 2a (AB047639 and
AX057395), genome 2b (AB030907 and AF238486), and genome 5a
(AF064490 and Y13184) reference sequences indicated a crossover
point at the beginning of the NS3 region, between nucleotides
3420 and 3440, depending on the method (
P value, <0.01 for
each method) (Fig.
3). Thus, the analysis by the Recombination
Detection Program version 2 corroborated the phylogenetic tree
results and showed that the 5' part of the R1 strain is related
to genotype 2k and the 3' part is related to genotype 5. Further
analyses did not reveal recombination with other genotypes.
Confirmation of the recombination point.
We ruled out the possibility of artifactual intra-PCR recombination
by amplifying by PCR fragments covering part of the E2 regions
to the beginning of the NS3 regions of the R1, genotype 2, and
genotype 5 strains. The reverse transcription-PCR kit (QIAGEN)
was used with 140 µl of serum HCV RNA from the patient
infected with the R1 strain. The sets of primers used were as
follows: (i) a genotype 2-specific sense primer and a genotype
5-specific antisense primer (S1-SW-G2 and AS1-SW-G5), (ii) genotype
2-specific sense and antisense primers (S1-SW-G2 and AS1-SW-G2),
and (iii) genotype 5-specific sense and antisense primers (S1-SW-G5
and AS1-SW-G5) (Table
1). The R1 strain sequence was successfully
amplified only when the reverse transcription-PCR used a type
2-specific sense primer and a type 5-specific antisense primer,
while the genotype 2 strain sequence was successfully amplified
with the type 2-specific primers and the genotype 5 strain sequence
with the type 5-specific primers (data not shown). The PCR product
obtained with the type 2-specific sense primer and the type
5-specific antisense primer was sequenced; this analysis confirmed
the same recombination point.
We have characterized a new HCV-2/5 recombinant genome that was identified because of a difference between the results from E2 and NS5B genotyping. Neither genotype 2 nor genotype 5 strains were found in the serum of the patient infected with R1, suggesting that she was contaminated directly by the R1 strain or that the recombinant strain had replaced the parental strains. The genotype 5-related sequence of the 3' region from the R1 strain diverges from the other genotype 5 sequences, clustering as subtype 5a. This finding suggests that other HCV-5 subtypes remain to be characterized. Similarly, our analyses of the E2 region or of the sequence from the 5' UTR to NS2 indicate that the R1 strain belongs to genotype 2, but the subtype is unknown. Our recent work with genotype 2 in our area has shown that this genotype varies greatly. Eight subtypes have been described, and more than 15% of the reported strains are uncharacterized (17). Salemi and Vandamme have demonstrated lower phylogenetic analysis values for the 5' part of the HCV genome than for the NS5B region (11).
Although recombination may not appear to be common among natural populations of HCV, it must be taken into account as a cause of HCV genetic diversity, which may influence epidemiology and diagnosis. The recombinant strain type 2k/1b is spreading in Europe; 10 strains are described in the HCV database. No data are yet available on the response of this recombinant virus to therapy (5, 9). Genotyping is generally done with small fragments of the HCV genome. The HCV genotype determined directly influences the therapeutic strategy. The widespread existence of recombinant forms would considerably limit the use of genotyping assays that are based on single genome regions, such as the 5' UTR or the core gene. The genotype may be determined by analyzing regions of interest, like the targets of new inhibitors of the HCV NS5B or NS3 gene.
The entire genome was sequenced, and the recombination site was identified at the beginning of the NS3 region. Several RNA viruses, like the Picornaviridae and the dengue virus, have recombination sites in the region of the genome that codes for the first nonstructural protein (3, 13, 14, 18). The recombination sites of the previously described recombinant HCV strains are also at the NS2/NS3 junction. The NS2/NS3 junction could be a favorable site for generating recombination events, especially with genotype 2 (4, 5, 10).
In conclusion, these data could be most important for vaccine development, diagnosis, and therapeutic strategy.
Nucleotide sequence accession number.
The recombinant sequence determined in this study has been deposited in the EMBL database with accession number AM408911.

FOOTNOTES
* Corresponding author. Mailing address: Laboratoire de Virologie, Institut Fédératif de Biologie, INSERM U563, IFR30, 330 Ave. de Grande-Bretagne, TSA 40031, 31059 Toulouse Cédex 9, France. Phone: (33) 5 67 69 04 24. Fax: (33) 5 67 69 04 25. E-mail:
izopet.j{at}chu-toulouse.fr 
Published ahead of print on 31 January 2007. 

REFERENCES
1 - Colina, R., D. Casane, S. Vasquez, L. Garcia-Aguirre, A. Chunga, H. Romero, B. Khan, and J. Cristina. 2004. Evidence of intratypic recombination in natural populations of hepatitis C virus. J. Gen. Virol. 85:31-37.[Abstract/Free Full Text]
2 - Fried, M. W., M. L. Shiffman, K. R. Reddy, C. Smith, G. Marinos, F. L. Goncales, Jr., D. Haussinger, M. Diago, G. Carosi, D. Dhumeaux, A. Craxi, A. Lin, J. Hoffman, and J. Yu. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347:975-982.[Abstract/Free Full Text]
3 - Guillot, S., V. Caro, N. Cuervo, E. Korotkova, M. Combiescu, A. Persu, A. Aubert-Combiescu, F. Delpeyroux, and R. Crainic. 2000. Natural genetic exchanges between vaccine and wild poliovirus strains in humans. J. Virol. 74:8434-8443.[Abstract/Free Full Text]
4 - Kageyama, S., D. M. Agdamag, E. T. Alesna, P. S. Leano, A. M. Heredia, I. P. Abellanosa-Tac-An, L. D. Jereza, T. Tanimoto, J. Yamamura, and H. Ichimura. 2006. A natural inter-genotypic (2b/1b) recombinant of hepatitis C virus in the Philippines. J. Med. Virol. 78:1423-1428.[CrossRef][Medline]
5 - Kalinina, O., H. Norder, S. Mukomolov, and L. O. Magnius. 2002. A natural intergenotypic recombinant of hepatitis C virus identified in St. Petersburg. J. Virol. 76:4034-4043.[Abstract/Free Full Text]
6 - Legrand-Abravanel, F., K. Sandres-Saune, K. Barange, L. Alric, J. Moreau, P. Desmorat, J. P. Vinel, and J. Izopet. 2004. Hepatitis C virus genotype 5: epidemiological characteristics and sensitivity to combination therapy with interferon-alpha plus ribavirin. J. Infect. Dis. 189:1397-1400.[CrossRef][Medline]
7 - Manns, M. P., J. G. McHutchison, S. C. Gordon, V. K. Rustgi, M. Shiffman, R. Reindollar, Z. D. Goodman, K. Koury, M. Ling, and J. K. Albrecht. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958-965.[CrossRef][Medline]
8 - Martin, D. P., C. Williamson, and D. Posada. 2005. RDP2: recombination detection and analysis from sequence alignments. Bioinformatics 21:260-262.[Abstract/Free Full Text]
9 - Moreau, I., S. Hegarty, J. Levis, P. Sheehy, O. Crosbie, E. Kenny-Walsh, and L. J. Fanning. 2006. Serendipitous identification of natural intergenotypic recombinants of hepatitis C in Ireland. Virol. J. 3:95.[CrossRef][Medline]
10 - Noppornpanth, S., T. X. Lien, Y. Poovorawan, S. L. Smits, A. D. Osterhaus, and B. L. Haagmans. 2006. Identification of a naturally occurring recombinant genotype 2/6 hepatitis C virus. J. Virol. 80:7569-7577.[Abstract/Free Full Text]
11 - Salemi, M., and A. M. Vandamme. 2002. Hepatitis C virus evolutionary patterns studied through analysis of full-genome sequences. J. Mol. Evol. 54:62-70.[CrossRef][Medline]
12 - Sandres, K., M. Dubois, C. Pasquier, J. L. Payen, L. Alric, M. Duffaut, J. P. Vinel, J. P. Pascal, J. Puel, and J. Izopet. 2000. Genetic heterogeneity of hypervariable region 1 of the hepatitis C virus (HCV) genome and sensitivity of HCV to alpha interferon therapy. J. Virol. 74:661-668.[Abstract/Free Full Text]
13 - Santti, J., T. Hyypia, L. Kinnunen, and M. Salminen. 1999. Evidence of recombination among enteroviruses. J. Virol. 73:8741-8749.[Abstract/Free Full Text]
14 - Simmonds, P. 2004. Genetic diversity and evolution of hepatitis C virus15 years on. J. Gen. Virol. 85:3173-3188.[Abstract/Free Full Text]
15 - Simmonds, P., J. Bukh, C. Combet, G. Deleage, N. Enomoto, S. Feinstone, P. Halfon, G. Inchauspe, C. Kuiken, G. Maertens, M. Mizokami, D. G. Murphy, H. Okamoto, J. M. Pawlotsky, F. Penin, E. Sablon, I. T. Shin, L. J. Stuyver, H. J. Thiel, S. Viazov, A. J. Weiner, and A. Widell. 2005. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42:962-973.[CrossRef][Medline]
16 - Simmonds, P., E. C. Holmes, T. A. Cha, S. W. Chan, F. McOmish, B. Irvine, E. Beall, P. L. Yap, J. Kolberg, and M. S. Urdea. 1993. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J. Gen. Virol. 74:2391-2399.[Abstract/Free Full Text]
17 - Thomas, F., F. Nicot, K. Sandres-Saune, M. Dubois, F. Legrand-Abravanel, L. Alric, J. M. Peron, C. Pasquier, and J. Izopet. 2007. Genetic diversity of HCV genotype 2 strains in south western France. J. Med. Virol. 79:26-34.[CrossRef][Medline]
18 - Tolou, H. J., P. Couissinier-Paris, J. P. Durand, V. Mercier, J. J. de Pina, P. de Micco, F. Billoir, R. N. Charrel, and X. de Lamballerie. 2001. Evidence for recombination in natural populations of dengue virus type 1 based on the analysis of complete genome sequences. J. Gen. Virol. 82:1283-1290.[Abstract/Free Full Text]
Journal of Virology, April 2007, p. 4357-4362, Vol. 81, No. 8
0022-538X/07/$08.00+0 doi:10.1128/JVI.02639-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Pacini, L., Graziani, R., Bartholomew, L., De Francesco, R., Paonessa, G.
(2009). Naturally Occurring Hepatitis C Virus Subgenomic Deletion Mutants Replicate Efficiently in Huh-7 Cells and Are trans-Packaged In Vitro To Generate Infectious Defective Particles. J. Virol.
83: 9079-9093
[Abstract]
[Full Text]
-
Li, C., Lu, L., Wu, X., Wang, C., Bennett, P., Lu, T., Murphy, D.
(2009). Complete genomic sequences for hepatitis C virus subtypes 4b, 4c, 4d, 4g, 4k, 4l, 4m, 4n, 4o, 4p, 4q, 4r and 4t. J. Gen. Virol.
90: 1820-1826
[Abstract]
[Full Text]
-
Xu, Z., Fan, X., Xu, Y., Di Bisceglie, A. M.
(2008). Comparative Analysis of Nearly Full-Length Hepatitis C Virus Quasispecies from Patients Experiencing Viral Breakthrough during Antiviral Therapy: Clustered Mutations in Three Functional Genes, E2, NS2, and NS5a. J. Virol.
82: 9417-9424
[Abstract]
[Full Text]
-
Aaskov, J., Buzacott, K., Field, E., Lowry, K., Berlioz-Arthaud, A., Holmes, E. C.
(2007). Multiple recombinant dengue type 1 viruses in an isolate from a dengue patient. J. Gen. Virol.
88: 3334-3340
[Abstract]
[Full Text]